Published • loading... • Updated
Trial of fast-tracked new Parkinson's cell therapy hits 'critical'...
Summary by Parkinson's News Today
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Trial of fast-tracked new Parkinson's cell therapy hits 'critical'...
Aspen Neuroscience has completed dosing in the third and fourth groups of people with Parkinson’s disease receiving its new commercial-ready formulation of the cell therapy sasineprocel (ANPD001) in a small U.S. clinical trial. This brings the total number of adults with Parkinson’s who received sasineprocel in the ASPIRO trial (NCT06344026) to 15. The Phase 1/2a study, conducted at nine sites across the country, is testing the safety and tolera…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
